



Global Health  
EDCTP3

# Work Programme 2026: Calls for proposals and topics

Jean-Marie Vianney Habarugira  
Senior Scientific Officer, Global Health EDCTP3

Silvia Garcia  
Scientific Project Officer, Global Health EDCTP3

Co-funded by  
the European Union



# 2026 Working Programme

|



Adopted by the Governing Board of Global Health EDCTP3 on 2 December 2025



Includes 1 one-stage and 2 two-stage calls covering 6 topics



Includes a “mobilisation of research funds in case of public health emergencies”



Total indicative budget for Calls for proposals and other actions not subject to Calls for proposals: € 146.9M\*

\* Additional budget of Contributing Partner under discussion

# 2026 Working Programme – 3 open competitive calls, with 6 Topics

Calls	Topic Code	Call Topic Title	Budget (€)	Total budget (€)
01	HORIZON-JU-GH-EDCTP3-2026-01-TB-01-two-stage	Global Collaboration Action for the development of TB drugs for therapy and chemoprophylaxis in adults and children in sub-Saharan Africa	30 M	88.9 M
	HORIZON-JU-GH-EDCTP3-2026-01-LRTI-02-two-stage	Global Collaboration Action for Prevention and treatment of Lower Respiratory Tract Infections (LRTIs) in sub-Saharan Africa	33.9 M*	
	HORIZON-JU-GH-EDCTP3-2026-01-HIV-03-two-stage	Global collaboration action towards a better prevention, treatment and clinical management of HIV co-infections or co-morbidities in sub-Saharan Africa	25 M	
02	HORIZON-JU-GH-EDCTP3-2026-02-CH-01-two-stage	Global Collaboration Action on climate and health in sub-Saharan Africa	25 M	25 M
03 (single-stage)	HORIZON-JU-GH-EDCTP3-2026-03-SERP-01	Training networks for sustained capacity building related to ethics, regulatory and pharmacovigilance	15 M*	33 M
	HORIZON-JU-GH-EDCTP3-2026-03-DIGIT-02	Enhancing Integrated Research and Healthcare in sub-Saharan Africa Through Digital Innovation and Artificial Intelligence in SSA	18 M*	

- + Mobilisation of research funds in case of **Public Health Emergencies** € 1 M
- + HORIZON-JU-GH-EDCTP3-2026-KHUB-01-IBA: Expansion and consolidation of the EDCTP Knowledge Hub € 1 M

\*The budget for this call topic may increase, subject to confirmation of a contributing partner's contribution.

HORIZON-JU-GH-EDCTP3-2026-01-TB-01-Two-Stage

|

**Global Collaboration Action for the development of TB  
drugs for therapy and chemoprophylaxis in adults and  
children in sub-Saharan Africa**



# HORIZON-JU-GH-EDCTP3-2026-01-TB-01-two-stage

## Global Collaboration Action for the development of TB drugs for therapy and chemoprophylaxis in adults and children in sub-Saharan Africa

Research and Innovation Action (RIA)

Indicative call topic budget: EUR 30.0 M

Expected project size: to support up to 3 projects (around EUR 10.0 M per project)

### Call Deadlines

1. Stage: 4 March 2026, 17:00:00 Brussels time
2. Stage: 17 September 2026 17:00:00 Brussels time

### Expected outcomes

- Deliver results contributing to improve **TB-related outcomes** in adults and/or children in sub-Saharan Africa
- Lead to reduced burden of **MDR-TB and XDR-TB**, and/or improved TB interventions in **vulnerable populations**, particularly children



LEPROSY RESEARCH INITIATIVE



Global Health  
EDCTP3

# HORIZON-JU-GH-EDCTP3-2026-01-TB-01-two-stage

## Global Collaboration Action for the development of TB drugs for therapy and chemoprophylaxis in adults and children in sub-Saharan Africa

### Scope

**Phase IIa and beyond** clinical trials advancing new or improved TB regimens, including

- Shorter or improved regimens
- Chemoprophylaxis and/or combined interventions

### Additionally, proposals are encouraged to:

- Focus on **priority populations**, including women of childbearing potential and pregnant women, and particularly children, especially for assets in late-stage development
- Generate clinical data progressing development of new or improved treatment regimens for **MDR TB and XDR TB**
- Pulmonary, extrapulmonary and latent TB forms, drug-resistant, MDR and XDR TB, combination of chemoprophylaxis with vaccines, and combination of chemoprophylaxis with host-directed therapies
- Development of treatment of latent TB: focus on individuals with increased risk of **active disease progression**

# HORIZON-JU-GH-EDCTP3-2026-01-TB-01-two-stage

## Global Collaboration Action for the development of TB drugs for therapy and chemoprophylaxis in adults and children in sub-Saharan Africa

### Scope

- **Sex/gender and age differences** should be considered when relevant, especially for Phase III studies
- Treatment decision algorithms can be included, but not as primary objective
- Proposals can address co-infections or co-morbidities of TB, including HIV/AIDS, but not as the primary objective of the proposal.
- Implementation of solutions as soon as possible: granting authority will base funding decision on ranking of proposals considering **a portfolio approach**
- Post-Exposure Prophylaxis research – some of the projects that include a **leprosy** focus will be **cofunded** by the [Leprosy Research Initiative](#)



LEPROSY RESEARCH INITIATIVE



Global Health  
EDCTP3

# HORIZON-JU-GH-EDCTP3-2026-01-TB-01-two-stage

## Global Collaboration Action for the development of TB drugs for therapy and chemoprophylaxis in adults and children in sub-Saharan Africa

**Out of scope:** Development of prophylactic vaccines, diagnostics and monoclonal antibodies, Phase I a/b clinical trials of single and/or combination drugs, implementation research in early phase studies, preclinical studies

### Expected impact

- Contribute to achieve the reduction of disease burden in SSA through increased **international cooperation** among researchers and funders, catalyse research **synergies**, and leverage **resources and investment**.
- Proposals are expected to include the effective in-kind and/or financial contribution of **contributing partners**, in order to produce more meaningful and significant effects enhancing the impact of the related research activities.

Additional Information to all Call Topics are within the [Strategic Research & Innovation Agenda](#)



LEPROSY RESEARCH INITIATIVE



HORIZON-JU-GH-EDCTP3-2026-01-LRTI-02-Two-Stage

|

**Global Collaboration Action for Prevention and  
Treatment of Lower Respiratory Tract Infections  
(LRTIs) in sub-Saharan Africa**



# HORIZON-JU-GH-EDCTP3-2026-01-LRTI-02-two-stage

## Global Collaboration Action for Prevention and Treatment of Lower Respiratory Tract Infections (LRTIs) in sub-Saharan Africa

Research and Innovation Action (RIA)

Indicative call topic budget: EUR 33.9 M

Expected project size: to support up to 4 projects (around EUR 8.475M per project )

### Call Deadlines

1. Stage: 4 March 2026, 17:00:00 Brussels time
2. Stage: 17 September 2026 17:00:00 Brussels time

### Expected outcomes

Deliver results directed, tailored towards and contributing to strengthening the capacity of SSA health actors to address LRTIs, their associated complications and barriers to effective management

- Improve LRTI-related outcomes, including mortality and morbidity in SSA and/or
- Increase access to LRTI interventions in SSA

Advancing prevention and treatment of pathogens related to LRTI by evaluating safety, immunogenicity, efficacy and/or effectiveness of approved or novel preventive or therapeutic candidates

## Global Collaboration Action for Prevention and Treatment of Lower Respiratory Tract Infections (LRTIs) in sub-Saharan Africa

### Scope

Late-stage clinical studies (Phase IIb and after) advancing prevention and treatment of LRTI pathogens\* by evaluating safety, immunogenicity, efficacy and/or effectiveness of approved or novel preventive or therapeutic candidates

#### *At least one of the following points should be addressed:*

- Obtain evidence of immunogenicity, efficacy, safety or clinical utility on new or existing **preventive measures** against LRTI pathogens
- Obtain evidence of efficacy, safety or clinical utility on new or existing **treatment measures** against LRTI pathogens

#### **\*LRTI pathogens in scope:**

S. pneumoniae, H. influenzae, S. aureus, an K. pneumoniae, Mycoplasma pneumoniae, Chlamydia pneumoniae, human respiratory syncytial virus (RSV), adenovirus, rhinovirus/enterovirus, influenza A/B, human parainfluenza viruses, and human metapneumovirus

# HORIZON-JU-GH-EDCTP3-2026-01-LRTI-02-two-stage

## Global Collaboration Action for Prevention and Treatment of Lower Respiratory Tract Infections (LRTIs) in sub-Saharan Africa

### Scope

**In addition, at least one of the following points should be included:**

- Obtain evidence on new or existing preventive health solutions against LRTI for children (including maternal vaccination)
- Improvement of preventive and/or treatment measure's coverage, access, scaling-up and/or availability
- Implementation of existing intervention with demonstrated efficacy and safety in other regions, with generation of data on real-world effectiveness and cost-effectiveness
- Generate clinical data on host-strengthening interventions (non-specific effects of live attenuated vaccines, pre/probiotics, and/or other non-pharmaceutical interventions)

**Out of scope:** Development of antibiotics and diagnostics methods; any research on tuberculosis, cytomegalovirus (CMV), human coronaviruses and fungi; preclinical studies.

HORIZON-JU-GH-EDCTP3-2026-01-HIV-03-Two-Stage

|

**Global collaboration action towards a better prevention, treatment and clinical management of HIV co-infections or co-morbidities in sub-Saharan Africa**



# HORIZON-JU-GH-EDCTP3-2026-01-HIV-03-two-stage

## Global collaboration action towards a better prevention, treatment and clinical management of HIV co-infections or co-morbidities in sub-Saharan Africa

Research and Innovation Action (RIA)

Indicative call topic budget: EUR 25.0 M

Expected project size: to support up to 5 projects (around EUR 5.0M per project)

### Call Deadlines

1. Stage: 4 March 2026, 17:00:00 Brussels time
2. Stage: 17 September 2026 17:00:00 Brussels time

### Expected outcomes (*all required*)

1. Improved prevention and/or treatment outcomes for HIV-related co-infection(s) or co-morbidity/ies in SSA
2. Better integration of healthcare services and support programs related to HIV co-infection(s) or co-morbidity/ies for people living with HIV (PLWH) in different healthcare settings in SSA
3. Improved clinical management of PLWH and related co-infection(s) or comorbidity/ies, particularly safer and more effective polypharmacy use
4. Evidence supporting better-informed policy-making and guideline updates for HIV-related co-infection(s) or comorbidity/ies

# HORIZON-JU-GH-EDCTP3-2026-01-HIV-03-two-stage

## Global collaboration action towards a better prevention, treatment and clinical management of HIV co-infections or co-morbidities in sub-Saharan Africa

### Scope

- Late-stage clinical studies (Phase IIb or later) generating evidence on efficacy, immunogenicity, safety and/or clinical utility of novel/improved products that aim to prevent/treat co-infection or co-morbidity in HIV patients in SSA, including:
  - Prevention of HIV co-morbidity development or HIV disease advancement
  - Effective service integration in healthcare systems in SSA, including safer polypharmacy use
- Generating evidence to support public health decision-making, inform clinical guidelines and design relevant HIV policies
- Cost-effectiveness and implementation research, especially for new innovations such as long acting injectables or monoclonal antibodies (affordability and accessibility)

### Target Population:

People living with HIV, including advanced HIV disease (associated with comorbidities), patients on long term HIV treatment, all co-infections (except TB) and co-morbidities (including those attributed to interventions for HIV treatment), inclusive of vulnerable populations (e.g. PLWH with impaired organ function)

**Out of scope:** surveillance studies with new cohorts, studies focusing on development/evaluation of diagnostics, preclinical studies, intervention studies focusing solely on HIV prevention or treatment without addressing co-infections or co-morbidities

HORIZON-JU-GH-EDCTP3-2026-02-CH-01-Two-Stage

|

## **Global collaboration action on climate and health in sub-Saharan Africa**



# HORIZON-JU-GH-EDCTP3-2026-02-CH-01-two-stage

## Global collaboration action on climate and health in sub-Saharan Africa

Research and Innovation Action (RIA)

Indicative call topic budget: EUR 25.0 M

Expected project size: to support up to 5 projects (around EUR 5.0M per project)

### Call Deadlines

1. Stage: 4 March 2026, 17:00:00 Brussels time
2. Stage: 17 September 2026 17:00:00 Brussels time

### Expected outcomes

- Improved health outcomes related to climate-sensitive vector- and water-borne diseases in SSA (with a high and rising burden) and Europe (with a rapidly emerging endemic risk)
- Enhance evidence-based decision-making related to mitigating the impact of climate change on the health of SSA populations based on study data
- Increased engagement of communities and primary health care systems in lowering the burden of climate-sensitive vector- and water-borne diseases

# HORIZON-JU-GH-EDCTP3-2026-02-CH-01-two-stage

## Global collaboration action on climate and health in sub-Saharan Africa

### Scope

#### A/ Minimum one of the following should be included within the proposals:

**Clinical trials** (Phase IIb or III) or post-authorization effectiveness trials (phase IV) developing a preventive or therapeutic medicine, or vaccine against the climate-sensitive pathogens in scope

OR

**Large-scale implementation research** addressing climate-sensitive vector- or waterborne diseases and integration of climate, environmental and health system data

#### B/ In addition, *all of the following*:

1. Integration of OneHealth aspect into research (human, environmental and animal health) (EU guidelines for OneHealth incorporations, Package interventions)
2. Encompass primary health care systems, community health works and the community into the study
3. Inclusion of underserved and vulnerable populations (children under five, pregnant women, elderly, people with co-morbidities)

# HORIZON-JU-GH-EDCTP3-2026-02-CH-01-two-stage

## Global collaboration action on climate and health in sub-Saharan Africa

### Scope

#### C/ In addition, *at least two of the following points should be included:*

1. Include indigenous populations as defined per national/regional context
2. Study the impact of climate change on supply chains and access to medical countermeasures
3. Involve local, regional or national health and climate authorities/policymakers, bridging the gap between research and policymaking
4. Integrate research in national adaptation plans and National Health Emergency Plans
5. Include adaptations of primary health care systems to climate change, for example infrastructural improvements or the training of the primary care workforce

**Out of scope:** Climate or environmental research without clear health or disease outcome(s), studies not addressing vector- or water-borne diseases

HORIZON-JU-GH-EDCTP3-2026-03-SERP-01-Single-Stage

|

**Training networks for sustained capacity building related to ethics, regulatory and pharmacovigilance**



# HORIZON-JU-GH-EDCTP3-2026-03-SERP-01-Single-Stage

## Training networks for sustained capacity building related to ethics, regulatory and pharmacovigilance

Coordination and Support Action (CSA)

Indicative call topic budget: EUR 15.0 M (Lump sum funding approach)

Contributing partner: CEPI (subject to GB approval)

Expected project size: to support up to 10 projects (around EUR 1.5M per project)

### Call Deadline

02 September 2026

17:00:00 Brussels time

### Expected outcomes

Increased regulatory and research ethics oversight capacity of national and regional authorities in SSA to operate at WHO maturity level 3 (ML3) for clinical trial, registration and/or PV for medical products (therapeutics/vaccines)

### Proposals are additionally expected to lead to *at least two of the following outcomes*

1. Improved digital infrastructure including emerging digital tech (i.e. AI, big data) for assessment of clinical trials by RECs and regulatory authorities in SSA
2. Availability and accelerated use of digital tools and data analytics for real-time safety data monitoring, reporting, and timely PV data sharing across countries in SSA and globally (pre- and post-authorisation PV processes)
3. Harmonize and streamline research ethics processes within countries to better coordinate multi-centre trial reviews
4. Greater alignment and cooperation across countries in SSA regarding global standards in ethics, regulatory and PV
5. Greater preparedness for emergency use authorization (incl MEURI) through implementation of accelerated and harmonized processes

|

## Training networks for sustained capacity building related to ethics, regulatory and pharmacovigilance

### Scope (1)

1. **Provide scientific advice, enhancement of knowledge on assessing innovative clinical trial applications** (not limited to platform trials), and/or assessment of marketing authorization files, PV capabilities (including AI, big data), strengthening capacity for ethics committees' and/or regulatory agencies (that did not reach ML3) while benefitting from mentoring/peer support by ML3/ML4 agencies as part of the consortium
2. **Establish and strengthen training and twinning networks or a regional regulatory authority** dedicated to training ethicists and regulators (ensuring sustainable capacity for Ethics Committees, and/or Regulatory Authorities, and/or PV across SSA aligning with international standards)

**Out of scope:** Capacity building related to pharmaceutical/vaccines manufacturing activities (included but not limited to batch release, support for local manufacturing of active pharmaceutical ingredients (APIs) and technology transfer, diagnostic production, financing, strategic and policy support mechanisms for manufacturing).

*Note: the scope includes strengthening of NRAs capacity to carry out manufacturers inspections enabling registration and marketing authorization of medical products*

# HORIZON-JU-GH-EDCTP3-2026-03-SERP-01-Single-Stage

## Training networks for sustained capacity building related to ethics, regulatory and pharmacovigilance

### Scope (2): Additionally, proposals should address *minimum one* of the following:

- **Building national and/or regional/continental ethics and regulatory capacity to utilise digital technologies**, improving review and approval processes of clinical trial applications (including parallel ethics and regulatory review), and/or marketing authorisation of medical products
- **Improving integration of PV systems into national health systems** by building and utilizing **digital reporting mechanisms and data sharing** across SSA in alignment with international standards:

**Implementation of collaborative digital platforms** (accelerated use of digital reporting to support joint reviews and collaboration in PV, data sharing (i.e. ADRs) from site to national systems and beyond)

and  
/ or

**Improve safety reporting** through enhanced quality of adverse event reports and geographical coverage of reported data

and  
/ or

**Strengthen pre- and post-authorization PV systems** including risk-benefit analysis

- **Improving regulatory and ethics framework and emergency preparedness infrastructure** (harmonisation of processes, reliance, implementation and use of digital platforms for joint reviews)
  - Establishing continental and global ethics and regulatory peer support and twinning networks
  - Establishing continental and global regulatory innovation networks for alternative licensure pathways vision of “ONE WORLD, ONE DOSSIER”

HORIZON-JU-GH-EDCTP3-2026-03-DIGIT-02-Single-Stage

|

**Enhancing Integrated Research and Healthcare in sub-Saharan Africa Through Digital Innovation and Artificial Intelligence**



## Enhancing Integrated Research and Healthcare in sub-Saharan Africa Through Digital Innovation and Artificial Intelligence

Coordination and Support Action (CSA)

Indicative call topic budget: EUR 18.0 M (Lump sum funding approach)

Expected project size: to support up to 8 projects (maximum of EUR 2.25 M per project)

**Call Deadline**

02 September 2026  
17:00:00 Brussels time

### Expected outcomes (*at least two of the following*):

- Scaled-up implementation of validated digital innovations at national or sub-regional level
- Improved data interoperability and data harmonisation of electronic health records between different digital health systems according to international standards
- Integrated comprehensive roadmap for sustainable and scalable information of digital health tools into clinical trials and public health systems in SSA (aligning with international standards, local ethical standards and in the context of sharing best practices)
- Increased retention of skilled experts in digital health, epidemiology, bioinformatics, AI in SSA

|

## **Enhancing Integrated Research and Healthcare in sub-Saharan Africa Through Digital Innovation and Artificial Intelligence**

### **Scope**

1. Strengthen health systems, capacity and partnership to enhance development/use of existing and new digital health records and tools (e.g. machine learning, AI), aiming to prevent, detect or treat infectious diseases in SSA, enabling health care workers and policy makers to make informed clinical decisions or implement well-informed epidemic preparedness measures (favour low-risk digital/AI approaches)
2. Strengthen scale up of existing validated digital technologies in national and regional efforts across SSA for implementation at national or sub-regional level, while aligning with digital health strategies (international best practices)
3. Improved coordination between stakeholders promoting collaborative platforms and partnerships sharing data and knowledge between regions/countries in SSA (ideally with global partners)

### **Additionally, proposals should consider:**

- Knowledge sharing between countries with advanced systems and those with lower capacity (in terms of digital tools and skills) while applying international standards for data use and governance including data privacy and ownership
- Addressing societal impact and acceptability by concerned populations, demonstrate compliance with ethics requirements in involved SSA countries

## **Enhancing Integrated Research and Healthcare in sub-Saharan Africa Through Digital Innovation and Artificial Intelligence**

### **Additionally, proposals should consider:**

- Addressing audit of bias of the AI system and address sustainability of the project outcome (beyond project duration)
- Ensuring equity across involved countries in SSA and in relation to other countries with similar technologies
- Inclusion of hands-on practical capacity-building activities (preparing institutions/professionals to lead digital transformation efforts and health policy dialogues)
- Including clear plan of making digital tools accessible and affordable to users, public sharing of outcomes when possible and relevant
- Engaging communities and relevant stakeholders, most notably local key opinion leaders, researchers or clinical investigators, health care professionals, policy makers, public health authorities and end-users

**Rather than creating new technologies, the focus is on better use of what already exists by improving coordination, strengthening human capacity, and supporting evidence-based policies and investments that can unlock the true potential of digital health across the region.**

# Other actions not subject to call for proposals

## HORIZON-JU-GH-EDCTP3-2026: Expansion and consolidation of the EDCTP Knowledge Hub

- **Form of funding:** Grants not subject to calls for proposals
- **EU budget:** EUR one (1) million
- **Type of action:** Grant to identified beneficiary according to Financial Regulation Article 198(e) and Article 24(3) (a) of the Horizon Europe Regulation - Coordination and Support Action
- The University of Oxford is an identified partner to expand and consolidate **the EDCTP Knowledge Hub**. Building on over a decade of impactful collaboration with EDCTP programmes, TGHN provides a robust digital platform and a vast globally connected community that uniquely delivers capacity building, drives active knowledge sharing, and implementation of health research system strengthening across sub-Saharan Africa.
- The proposed scope of work is to support five priority areas identified in the programme logic where adding these interventions could help Global Health EDCTP3 achieve them with an in-built tracking mechanism. This scope of work also provides a direct and measurable way for Global Health EDCTP3 to implement **the WHO Global Action Plan for Clinical Trial Ecosystem Strengthening**. Generating strong return on investment by enabling immediate, ongoing and embedded delivery of this action plan.

# Other actions not subject to call for proposals

## Mobilisation of research funds in case of Public Health Emergencies

- **Form of funding:** Grants not subject to calls for proposals according to Article 198(b) for the Financial Regulation or grants subject to a call for proposal
- **Type of action:** RIA or CSA
- **Expected outcome:** Proposals should set out a credible pathway to contributing to one or several expected impacts of this Work Programme.

### Project results are expected to contribute to the following expected outcome:

Allow the European Union and sub-Saharan African countries to respond to Public Health Emergencies.

Work in this area should allow a faster research response to outbreaks of epidemic or pandemic infectious diseases. This will allow the EU and sub-Saharan African member countries of the EDCTP Association to respond to public health emergencies.

In case of a public health emergency, such as

- 1) a public health emergency of international concern (**PHEIC**) according to the World Health Organization; **or**
- 2) a public health emergency under **Regulation (EU) 2022/2371**; **or**
- 3) a public health emergency under applicable **national** frameworks and regulations)

# EDCTP Prizes 2027

|

## Awarded during EDCTP Forum 2027

EDCTP Prizes recognise **individuals and institutions** that exemplify the vision of the Global Health EDCTP3 Programme through innovation, leadership, and a deep **commitment to capacity building and by fostering equitable partnerships and delivering high-impact research in poverty-related diseases**.


1. Outstanding **Research Team** Prize (50,000€)
2. Outstanding **Female Scientist** Prize (20,000€)
3. Scientific **Leadership Prize European woman** (15,000€)
4. Scientific **Leadership Prize Sub-Saharan African woman** (15,000€)
5. Scientific **Leadership Prize Sub-Saharan Africa man** (15,000€)
6. Scientific **Leadership Prize European man** (15,000€)

- Eligible individuals and teams encouraged to apply
- Call for applications in 2026
- (to be announced via Global Health EDCTP3 website and social media)
- Application templates via EU Funding & Tender Portal
- Prizes to be awarded in 2027




Global Health  
EDCTP3

# Q&A session



Co-funded by  
the European Union





Global Health EDCTP3

# Info Day 2026

5 February 2026 online

Break time  
See you  
at 11:05



Co-funded by  
the European Union